Cellbion KRX:308430KOSDAQ
셀비온 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked21since Sep 11
In Q2 2026, Cellbion reported revenue of ₩472m, up 16.7% year on year, and an operating loss of ₩2.6bn. Cellbion (셀비온) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
Filing signals Clinical trial filing 4 quarters of losses Screener
Cellbion quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩472m | +16.7% | −₩2.6bn | ₩14.4bn |
| Q1 2026 | ₩613m | +27.7% | −₩2.4bn | −₩2.4bn |
| Q4 2025 derived | ₩382m | -32.6% | −₩2.5bn | −₩2.4bn |
| Q3 2025 | ₩679m | -42.3% | −₩2.0bn margin −294.1% | −₩1.8bn |
| Q2 2025 | ₩404m | +17.6% | −₩2.1bn | −₩1.9bn |
| Q1 2025 | ₩480m | +138.3% | −₩1.7bn | −₩1.4bn |
| Q4 2024 derived | ₩567m | +23.2% | −₩2.2bn | −₩2.4bn |
| Q3 2024 | ₩1.2bn | +277.5% | −₩1.7bn margin −146.6% | −₩1.7bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Cellbion top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest Cellbion news Korean headlines
-
셀비온, 전립선암 치료제 3상 승인 발판으로 글로벌 파트너링 확대
1 more on this story · 1 outlets
- 셀비온, 전립선암 치료제 3상 승인 발판으로 글로벌 파트너링 확대알파경제 · Oct 7 09:18
-
MajorBreaking셀비온, 전립선암 치료제 '177Lu-DGUL' 국내 임상 3상 승인…150명 대상
1 more on this story · 1 outlets
- 셀비온, 전립선암 치료제 임상 3상 IND 승인전자신문 · Sep 29 14:31
-
Major셀비온, AI 기반 방사성의약품 플랫폼 국책과제 선정
1 more on this story · 1 outlets
- 셀비온, 산업부 ‘AI 기반 방사성의약품 개발’ 국책과제 선정이데일리 · Sep 14 09:04